A Three-Gene Signature for Predicting the Prognosis of Patients Treated with Transarterial Chemoembolization (TACE) and Identification of PD-184352 as a Potential Drug to Reverse Nonresponse to TACE

Figure 6

Differences in risk score among different clinical subgroups of patients treated with TACE. With reductions in recurrence months (a, b), cirrhosis (c, d), tumor size (e, f), and TNM staging (g, h), the risk score showed an upward trend.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)